Baird Downgrades VistaGen Therapeutics (VTGN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VTGN Hot Sheet
Price: $0.18 -5.26%
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Baird analyst Brian Skorney downgraded VistaGen Therapeutics (NASDAQ: VTGN) from Outperform to Neutral with a price target of $0.25.
For an analyst ratings summary and ratings history on VistaGen Therapeutics click here. For more ratings news on VistaGen Therapeutics click here.
Shares of VistaGen Therapeutics closed at $1.07 yesterday.
You May Also Be Interested In
- Vistagen taps GATC Health's AI platform for drug development programs
- Morgan Stanley Downgrades BE Semiconductor (BESI:NA) (BESIY) to Equalweight
- Goldman Sachs Downgrades Ola Electric (OLAELEC:IN) to Sell
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
